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to similar rates as matched related and matched unrelated
recipients. Infection and relapse remain the most common
causes of mortality amongst all 3 groups, suggesting that
further investigation is warranted to reduce the incidences
of both outcomes.
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Background: Transfusion support after allogeneic transplan-
tation is closely associated with morbidity, cost and may also
affect long-term outcome. To better predict the determi-
nants of hematopoietic recovery of allogeneic hematopoietic
stem cell transplantation (HSCT) recipients, we analyzed 214
consecutive patients at our institution from January 2012 to
December 2013.
Patients and methods: We evaluated surrogate param-
eters for adequate hematopoietic recovery on day 100:
Hemoglobin ≥10 g/dl, packed red blood cells (PRBCs) trans-
fusion independence, platelets transfusion independence and
independence from granulocyte colony stimulating factor
(GCSF) support. We excluded patients who experienced early
(in the first 4 months) relapse (n = 28), non-relapse mortal-
ity (n = 28) or who had prolonged hospital stay before day
100 for transplant related complications (n = 54). One hundred
and four patients had uneventful recovery through day 100.
The majority of patients received Fludarabine and melphalan
conditioning (88%). Approximately one third each of the pa-
tients had HLA-identical related, HLA-matched unrelated
donors or underwent haplo-cord transplantation. Recipi-
ents of HLA-identical related or unrelated donor transplant
received alemtuzumab and post-transplant tacrolimus. Haplo-
cord recipients received thymoglobulin and post-transplant
tacrolimus and mycophenolate. The statistical analyses were
performed using STATA v14.1 (Stata Corp, TX, USA). Contin-
uous variables were compared using two-sided t-tests and
categorical variables were compared using Pearson c2 and Fis-
her’s exact tests. Differences were considered significant at
P-values < .05.
Results: There was a significant and marginally significant
correlation between Major ABO incompatibility and plate-
lets (OR = 4.7, P = .043) and PRBCs (OR = 2.6, P = .053)
transfusion dependence. CMV viremia significantly corre-
lated with GCSF dependency (OR 3.0, P = .037), while acute
GVHD significantly correlated with prolonged anemia (OR 3.7,
P = .005). There was no effect of graft type alone on hema-
topoietic recovery.
Conclusion: Major ABO incompatibility, CMV viremia
and acute GVHD are major predictors of prolonged hemato-
poietic recovery. Hematopoietic recovery of umbilical
cord blood is similar to adult matched related and unre-
lated grafts.
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Background: Tacrolimus (FK) has become one of the key
calcineurin inhibitors routinely used to reduce the risk of
graft-versus-host-disease in patients undergoing allogeneic
stem cell transplant (SCT). As non-ablative regimens have
increased the number of transplants in the geriatric popu-
lation, the data from initial studies may not accurately reflect
our current transplant patients. Although the mechanism
of action in elderly patients is similar, the metabolism and
tolerability may be different. The narrow therapeutic index,
drug interactions, and metabolism via the CYP450 pathway
present unique challenges to achieving therapeutic drug
levels. Current dosing at our institution relies exclusively
on actual body weight (ABW) without taking into account
age, gender, serum albumin, and ideal body weight (IBW).
With this retrospective study, we explore the impact these
factors may have on tacrolimus serum concentrations and
associated toxicities.
Methods: We performed a chart review of patients over the
age of 18 who received tacrolimus as part of their allogene-
ic SCT at our center between 2014 and 2017. The following
variables were obtained from the medical records: age, gender,
ABW, height, IBW, initial FK dose, serum albumin, and FK
trough levels within the first 2 weeks. Patients who did not
have FK levels drawn within 5 days of starting treatment,
those who received concomitant CYP inhibitors without dose
adjustment, and those who died within 30 days from SCT were
excluded.
Results: Ninety-five patients met the criteria of which 59
were males and 36 females. Forty-six patients were
supratherapeutic at first trough and 76 were supratherapeutic
at either the first, second, or third level. Of the patients
with supratherapeutic levels, 34.2% had clinical toxicity
(n = 26). Male patients (P = .0006) and patients over age 65
(P = .0399) were more likely to be supratherapeutic at first
tacrolimus trough. After adjusting for age and gender, the
odds of having a supratherapeutic FK trough were 3.1 times
higher for every .5 mg increase with ABW dosing (when
using IBW as baseline).
Conclusions: The current patient population undergoing al-
logeneic SCT requires a revised strategy for optimal care. The
data presented here suggests male gender and age over 65
are predictive of having a supratherapeutic first FK trough
which may favor the use of a lower starting dose. Similarly,
the higher supratherapeutic events in patients with a greater
difference between ideal and actual weights hints at im-
proved dosing when the IBW is used in overweight patients.
Our study suggests that age, gender, and IBW should be fac-
tored into tacrolimus dosing to prevent overtreatment and
toxicities. Further prospective studies are needed to confirm
these observations.
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Background: Allogeneic stem cell transplantation (allo-
HSCT) is a high-cost procedure, mainly represented by
length of hospitalization, as well as hospital readmissions.
Different types of alternative donor may impact differently
on the costs of this procedure. Objective: To evaluate the
impact of the cell source, type of transplant and age at the
time of hospitalization in different types of alternative
allo-HSCT.
Method: A retrospective analysis of consecutive patients sub-
mitted to allo-HSCT at our institution from Jan/2010 to
Jan/2017.
Results: 188 patients were included in our analysis, 73
children and 115 adults. Regarding the type of transplant,
72 were haploidentical(haplo-HSCT), 82 Matched-unrelated
donor (MUD) and 34 umbilical cord blood (UCB). Regarding
the cell source, 57 patients (30.3%) received mobilized
peripheral blood cells, 98 (52.1%) bone marrow source
(BM). Regarding the conditioning regimen, 94 (50%) were
myeloablative, 48 (25.5%) non-myeloablative and 46 (24.4%)
were reduced intensity regimen (RIC). In our population,
readmission until day+100 correlated with worse overall
survival (P = .006). The median length of stay in the entire
group was 56 days until D +100 and 60% of patients who
had been discharged were readmitted. In the pediatric
group, it was 65 days and in the adults group 52 days.
Regarding the type of transplant, in the MUD group, 41/63
(65%) of those who had been discharged were readmitted
and 19/82 (23.1%) died before day +100. The median length
of hospitalization was 50 days. In the haplo-HSCT group,
9/72 (12.5) died before day +100, 35/63 (55.5%) of patients
were readmitted, with a 59-day hospitalization time. In the
UCB group, 10/34 (29.4%) died before day +100, 66.6% of
alive patients were readmitted before day +100 with a
66.5-day hospitalization time. There was a statistically sig-
nificant difference when compared MUD versus UCB (P = .027),
with no statistical difference between MUD versus
haploidentical (P = .305) or cord blood versus haploidentical
(P = .152). Regarding the conditioning regime, in the
myeloablative group, 58.3% were readmitted, with a 57.5
day-stay. In the non-myeloablative group, 61.3% were read-
mitted with a 54-day stay and in the RIC group, 68.5% were
readmitted, with a 56-day stay. Regarding the cell source,
63.4% of the patients who used peripheral blood were
readmitted, with a 57-day stay and 59.5% of those who
used BM were readmitted, with 51.5-day stay, compared to
66.6% of those who used cord blood, with hospitalization
length of 66.5 days.
Conclusion: In our population, we found no statistically dif-
ference in hospitalization length between MUD and haplo-
HSCT, and cord blood correlated with longer hospitalization
compared to MUD. More studies on cost effectiveness among
different types of alternative donors need to be carried out,
especially in low-income countries.
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Background: Many variables may affect outcome following
hematopoietic stem cell transplant (HSCT). Absolute lym-
phocyte count (ALC) after HSCT might be predictive of acute
Graft Versus Host Disease (aGVHD), non-treatment related
mortality (NTRM) and overall survival (OS). Two studies, one
by Gul et al. (2015) [1] and another by Haesook et al. (2015)
[2], showed that lower day+30 ALC correlated with poorer
OS, increased NTRM and severe aGVHD.
Objective: To conduct a review of allogeneic HSCT patients
performed at our institution from 2010 to 2017, in an attempt
to validate the results Gul and Haesook.
Methods: We identified 184 patients who underwent
T-cell replete, allogeneic HSCT. The recipient was female
(n = 71), the donor was a sibling (n = 55) or MUD (n = 129).
No haploidentical transplants were included in this analy-
sis. Myeloablative conditioning (n = 86) consisted of
Fludarabine 50 mg/m2/day d−6 to d−2, Busulfan 3.2 mg/kg/
day d−5 to d−2 and TBI 200 cGy/day on d−1 and d0.
Reduced intensity conditioning (n = 85) consisted of
Fludarabine 30 mg/m2/day d−6 to d−2 and Busulfan 3.2 mg/
kg/day d−3 and d−2. Other conditioning regimens were
given to 13 recipients. All patients received post-transplant
immunosuppression with mycophenolate mofetil and
tacrolimus. All recipients received anti-microbial prophylax-
is with ciprofloxacin (or another fluoroquinolone), fluconazole
and acyclovir.
Results:
aGVHD No aGVHD Total Incidence
of aGVHD
Day +30 ALC ≤.4 × 109
cells/L
23 60 82 .28
Day +30 ALC >.4 × 109
cells/L
28 73 101 .28
Total 51 133 184 P = .99
Day +30 ALC ≤.2 × 109
cells/L
5 28 32 .16
Day +30 ALC >.2 × 109
cells/L
46 105 152 .30
Total 51 133 184 P = .07
Median Overall Survival (days)
Day +30 ALC ≤.2 × 109 cells/L 183
Day +30 ALC ≤.4 × 109 cells/L 253
Day +30 ALC >.4 × 109 cells/L 243
At d+30 after transplant the ALC with either a .4 or .2 thresh-
old failed to predict outcome in our patients. In contrast to
the study by Gul an ALC ≤.2 showed a trend to less aGVHD.
Conclusion: Our results failed to confirm that day+30 ALC
≤.4 × 109 cells/L or ≤.2 × 109 cells/L is predictive of aGVHD. Par-
adoxically using a cutoff of ≤.2 × 109 cells/L showed a trend
towards less aGVHD in our study.
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